CVS Health stock: Wall Street Zen downgrades CVS Health stock to Buy
Published on 10/23/2026 at 16:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSWall Street Zen rating change
- Wall Street Zen downgraded CVS Health from strong-buy to buy on October 19, 2026.
- Adjusted earnings per share reached USD 2.58 in the second quarter of 2026, versus USD 1.87 expected.
- CVS Health stock costs EUR 83.79 at Lang & Schwarz on October 23, 2026 at 4:03 p.m. CEST, 0.01 percent above the Xetra close of October 22, 2026.
Wall Street Zen downgraded CVS Health from strong-buy to buy on October 19, 2026, according to MarketBeat. The change adds a more cautious analyst signal ahead of the company's third-quarter results. At Lang & Schwarz, CVS Health stock was trading at EUR 83.79 on October 23, 2026 at 4:03 p.m. CEST, 0.01 percent above the Xetra close of October 22, 2026.
Second-quarter revenue climbed
CVS Health reported USD 106.10 billion in revenue for the second quarter of 2026, up 7.30 percent from the prior-year quarter, according to MarketBeat. Adjusted earnings per share came to USD 2.58, compared with the USD 1.87 consensus estimate, a USD 0.71 difference. The result gives the rating change a fundamental counterpoint, even as the analyst action remains the more recent development.
Stock remains below its high
On the primary exchange, CVS traded at USD 93.94 on October 23, 2026 at 10:10 a.m. ET. Its 52-week range was USD 69.51 to USD 110.68, placing the stock 15.12 percent below the high and 35.15 percent above the low. The euro quotation and the US quotation are separate market views and are not combined in one performance calculation.
Valuation and reporting date
CVS Health had a market capitalization of USD 120.1 billion and a price-to-earnings ratio of 24.86 as of October 23, 2026. The company will discuss third-quarter 2026 results on November 4, 2026, at 8:00 a.m. ET, according to CVS Health. The event is the next scheduled reporting date identified by the company.
What the rating change means
The rating move is a change in direction from strong-buy to buy, not a new price target. The second-quarter figures provide a quantified operating backdrop: revenue increased 7.30 percent, while adjusted earnings per share exceeded consensus by USD 0.71. For investors, the November 4 reporting date is the next concrete test of whether that earnings strength continued into the third quarter.
CVS Health stock stays near its daily level
The euro quote was only 0.01 percent above the Xetra close of EUR 83.78 from October 22, 2026. The modest difference keeps the day's price movement below the threshold for a directional headline, while the analyst rating and upcoming results date provide the more relevant points of reference.
The further course of trading is shown by the continuously updated real-time quote of CVS Health stock.
CVS Health stock facts
- Company: CVS Health Corp.
- ISIN: US1266501006
- Ticker: CVS
- Primary exchange: NYSE
- Price Lang & Schwarz as of October 23, 2026, 4:03 p.m. CEST: EUR 83.79
- Change versus Xetra close: plus 0.01 percent
- Xetra close October 22, 2026: EUR 83.78
- Market capitalization: USD 120.1 billion (as of October 23, 2026)
- 52-week range: USD 69.51-110.68 (as of October 23, 2026)
- Next earnings date: November 4, 2026
Market context: Market report S&P 500.
